PTC/SB/08s (08-03.)
Approved for use through 07/31/2008, OMB 0851-0031
U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwalk Reduction Act of 1995, no persons are required to regional to a collection of information unless of contains a valid CMB control number.

Application Number

Filling Date

INFORMATION DISCLOSURE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Filing Date
First Named Inventor Andreas Buchmann
Art Unit
Examiner Name
Attorney Docket Number SCH-16767

				U.S	.PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applica of cited Document		Relev	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	
	1	4867946		1989-09-19	Gross et al.				
	2	5424035		1995-06-13	Hones et al.		Relate	is to EP 0618443	
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information	please click the	Add button.		Add	
			U.S.P	ATENT APPL	ICATION PUB	LICATIONS		Remove	_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document		Relev	s,Columns,Lines where ant Passages or Releves Appear	
	1	20040162690		2004-08-19	Lee				
If you wisl	h to a	dd additional U.S. Publ	ished Ap	plication citati	on information	please click the Ad	d buttor	n. Add	
				FOREIGN PA	TENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	76
	1	0 323 673	EP		1989-07-12	Walker Scientific E B.V.	urope		С
	2	0 495 379	EP		1992-07-22	Carl Neumeister G	imbH	English Abstract Included	c

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99) Art Unit Examiner Name Attorney Docket Number | SC1+16767

	3	0 84	0 123	EP		1998-05-06	Cell Diagnostica, Gesellschaft fur angewandte	English Abstract Included	
	4	99/4	1596	wo		1999-08-19	77 Elektronika Muszeripari KFT.		
	5	03/0	29813	wo		2003-04-10	Priorics AG		
If you wis	h to a	dd add	ditional Foreign P	atent Document	citation	information pl	ease click the Add butto	n Add	
				NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner linitials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								Ţ5
1									
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a									

1 See Nni Code of USPTO Patent Documents at twee USPTO_GOUY or MPEP 90104. Enter of tions that issued the document, by the two-letter of the Southern See The S

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Filing Date First Number Inventor Andreas Budmann Art Unit Examiner Name Attorney Docket Number I SCH-16767

CERTIFICATION STATEMENT

Ficase see 3/	CFR 1.01	and 1.50 to II	lake tile appropriat	ie seiection(s).	

That each item of information contained in the information disclosure statement was first cited in any communication

from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(a/1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Total of the signature.							
	Signature	/jab/	Date (YYYY-MM-DD)	2006-08-03			
	Name/Print	James A. Balazs	Registration Number	47401			

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.